Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2000
04/06/2000CA2342981A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
04/06/2000CA2342603A1 Antibiotic compositions for treatment of the eye, ear and nose
04/06/2000CA2340130A1 Liquid pharmaceutical for oral delivery
04/06/2000CA2311462A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
04/05/2000EP0990442A1 Therapeutic treatment for chronic myeloid leukemia and active lymphoid leukemia
04/05/2000EP0990437A1 Aerosol compositions
04/05/2000EP0990038A1 New human lysophospholipase
04/05/2000EP0990031A2 Tumor necrosis factor receptor 5
04/05/2000EP0989993A1 Tartrate salt of a substituted dipeptide as growth hormone secretagogue
04/05/2000EP0989864A1 Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
04/05/2000EP0989862A1 Pharmaceutical composition with antiviral activity containing an hydroxymic acid derivative and an antiviral agent
04/05/2000EP0989859A1 Cns neuroregenerative compositions and methods of use
04/05/2000EP0989852A1 Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
04/05/2000EP0989849A2 Therapeutic nanospheres
04/05/2000EP0989848A2 Film-coated tablet for improved upper gastrointestinal tract safety
04/05/2000EP0989847A1 Anti-tumoral therapy agent
04/05/2000EP0989845A1 Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
04/05/2000EP0733072B1 Antibody against carcinoembryonic antigen (cea)
04/05/2000CN1249743A Arylsulfonylamino hydroxamic acid derivs
04/05/2000CN1249691A Immobilized activity stabilized LHRH-antagonist complexes, method for production thereof
04/05/2000CN1249682A Use of angiotension II antagonists to treat symptomatic heart failure
04/04/2000US6046341 An active drug having affinity for vasopressin and/or oxytocin receptors
04/04/2000US6046331 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
04/04/2000US6046234 Formulations and methods of reducing toxicity of antineoplastic agents
04/04/2000US6046228 Include 1,2-dithiane and 1,2 dithiolane compounds, the ring sulfur atoms may be present in the sulfur oxide or sulfone state, useful for inhibiting retrovirus replication
04/04/2000US6046191 Combination
04/04/2000US6046187 Use of glucocorticosteroids in methods and formulations for prolonging and/or reactivating local anesthesia or local anesthesia previously induced by a local anesthetic agent
04/04/2000US6046183 Synergistic mixture of finasteride and doxazosin
04/04/2000US6046175 Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
04/04/2000US6046174 Tryptophanyl tRNA synthetase, trpS, of Streptococcus pneumoniae
04/04/2000US6046159 Formulations and methods of reducing toxicity of antineoplastic agents
04/04/2000US6046030 For the treatment of neurological disorders such as alzheimer's disease, multiple sclerosis and abnormal neural development; endocrine disorders such as diabetes; and heart disease, among others and diagnostic assays for such
04/04/2000US6045999 Transcription factor E2F-4
04/04/2000US6045829 Having increased rate and uniformity of absorption in vivo
04/04/2000US6045827 Treatment of equine laminitis
04/04/2000US6045807 Method for production of neuroblasts
04/04/2000US6045802 Antitumor agents treating cancer
04/04/2000US6045792 Human proteins kinases
04/04/2000CA2246162C Modulation of th1/th2 cytokine expression by ribavirin.rtm. and ribavirin.rtm. analogs in activated t-lymphocytes
04/04/2000CA2031129C Chimeric antibody for detection and therapy of infectious and inflammatory lesions
03/2000
03/30/2000WO2000017644A1 Ndp
03/30/2000WO2000017641A1 Gpr10 as a target for identifying weight modulating compounds
03/30/2000WO2000017398A1 Parallel selex
03/30/2000WO2000017394A1 Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
03/30/2000WO2000017393A1 Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
03/30/2000WO2000017392A1 Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases
03/30/2000WO2000017387A1 Production and use of antimicrobial agents
03/30/2000WO2000017369A2 Alzheimer's disease secretase
03/30/2000WO2000017362A1 Human interleukin-b50, therapeutic uses
03/30/2000WO2000017358A2 Human chaperone proteins
03/30/2000WO2000017354A1 Human isre-binding protein
03/30/2000WO2000017353A1 Ucp4
03/30/2000WO2000017348A1 G protein-coupled receptor agonists or antagonists
03/30/2000WO2000017232A2 Regulatory protein from human keratinocytes
03/30/2000WO2000017211A1 Phosphonic acids derivatives as inhibitors of ptp-1b
03/30/2000WO2000017165A1 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
03/30/2000WO2000017164A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
03/30/2000WO2000017161A1 Cyclic ester or amide derivatives
03/30/2000WO2000017159A1 Arylsulfonanilide ureas
03/30/2000WO2000016801A1 Methods of downmodulating the immune response to therapeutic proteins
03/30/2000WO2000016796A1 Chemokine receptor antagonist and cyclosporin in combined therapy
03/30/2000WO2000016794A1 Neuroimmunophilins for selective neuronal radioprotection
03/30/2000WO2000016777A1 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
03/30/2000WO2000016768A1 Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis
03/30/2000WO2000016761A2 Serotonergic 5ht2 agonists for treating glaucoma
03/30/2000WO2000016760A2 New use of prostaglandin e2 antagonists
03/30/2000WO2000016631A1 Murf2
03/30/2000WO2000016626A1 A method of treating cancer
03/30/2000WO2000007576A3 INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
03/30/2000WO2000002584A3 Cancer treatment methods using antibodies to aminophospholipids
03/30/2000WO2000000609A3 Molecules associated with apoptosis
03/30/2000WO2000000186A8 Method of treating topical ailments
03/30/2000WO2000000182A3 Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies
03/30/2000WO2000000120A9 Methods and transdermal compositions for pain relief
03/30/2000WO1999066937A9 Erythromycin compositions
03/30/2000WO1999066918A9 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
03/30/2000WO1999064593A3 Cell cycle regulation proteins
03/30/2000WO1999060127A9 Il-17 homologous polypeptides and therapeutic uses thereof
03/30/2000WO1999055831A3 Adenoviral vectors for treating disease
03/30/2000WO1998053846A9 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
03/30/2000DE19856261C1 Detection of gamma-secretase by detection of A-beta peptide useful for determining gamma-secretase activity and for identifying inhibitors
03/30/2000DE19844547A1 Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Polycyclic Dihydrothiazole, processes for their preparation and their use as medicaments
03/30/2000DE19844162A1 Medicament combination for treating erectile dysfunction, containing sildenafil and blood flow behavior improving agent, e.g. midodrine, to improve effect at lower dosages
03/30/2000CA2689373A1 G protein-coupled receptor antagonists
03/30/2000CA2345378A1 Neuroimmunophilins for selective neuronal radioprotection
03/30/2000CA2345088A1 Gpr10 as a target for identifying weight modulating compounds
03/30/2000CA2344927A1 Phosphonic acids derivatives as inhibitors of ptp-1b
03/30/2000CA2344670A1 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
03/30/2000CA2344657A1 Human isre-binding protein
03/30/2000CA2344370A1 Chemokine receptor antagonist and cyclosporin in combined therapy
03/30/2000CA2344288A1 Parallel selex
03/30/2000CA2344150A1 Serotonergic 5ht2 agonists for treating glaucoma
03/30/2000CA2343916A1 Methods of downmodulating the immune response to therapeutic proteins
03/30/2000CA2343360A1 Human cytoskeleton associated proteins
03/30/2000CA2343004A1 Alzheimer's disease secretase
03/30/2000CA2342957A1 Regulatory protein from human keratinocytes
03/30/2000CA2341036A1 Cyclic ester or amide derivatives
03/29/2000EP0988863A2 Stable complexes of poorly soluble compounds
03/29/2000EP0988548A1 Inhibition of the src kinase family pathway as a method of treating hbv infection and hepatocellular carcinoma
03/29/2000EP0988382A1 Human protein phosphatase ii-c-like protein
1 ... 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 ... 1151